Rocket Pharmaceuticals, Inc. (RCKT): Total Liabilities
$53.23M
As of 2025-12-31
$54.27M
As of 2026-06-30
-5.0%
3-year compound annual growth
-9.4%
5-year compound annual growth
+28.0%
10-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $53.23M | -17.4% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $64.47M | -12.6% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $73.77M | +18.7% | 2025-02-27, Balance as of period end |
| 2022-12-31 | $62.12M | +46.9% | 2024-02-27, Balance as of period end |
| 2021-12-31 | $42.30M | -51.6% | 2023-02-28, Balance as of period end |
| 2020-12-31 | $87.31M | +34.7% | 2022-02-28, Balance as of period end |
| 2019-12-31 | $64.82M | +13.2% | 2021-03-01, Balance as of period end |
| 2018-12-31 | $57.28M | n/m | 2020-03-06, Balance as of period end |
| 2017-12-31 | $4.63M | -91.8% | 2019-03-08, Balance as of period end |
| 2016-12-31 | $56.48M | n/m | 2018-03-07, Balance as of period end |
| 2015-12-31 | $4.51M | -56.1% | 2017-03-16, Balance as of period end |
| 2014-12-31 | $10.28M | n/a | 2016-03-23, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Rocket Pharmaceuticals, Inc. (RCKT) | 2025-12-31 | $53.23M | -17.4% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $71.53B | -6.1% |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | $10.78M | -5.9% |
| Pfizer Inc (PFE) | 2025-12-31 | $121.39B | -2.8% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $117.67B | +8.3% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $99.59M | +24.7% |
| Provectus Biopharmaceuticals, Inc. (PVCT) | 2025-12-31 | $7.00M | +0.4% |
| Lisata Therapeutics, Inc. (LSTA) | 2025-12-31 | $3.14M | -44.7% |
| Heron Therapeutics, Inc. (HRTX) | 2025-12-31 | $241.54M | -9.5% |
Compare RCKT, BMY, TXMD, PFE side by side · Screen every company in Pharmaceutical Preparations ↗